Artículos por temáticas

Characterization of forebrain neurons derived from late-onset Huntington's disease human embryonic stem cell lines.

Niclis JC, Pinar A, Haynes JM, Alsanie W, Jenny R, Dottori M, Cram DS.

Front Cell Neurosci. 2013 Apr 5;7:37. doi: 10.3389/fncel.2013.00037.

Rising serum thyroxine levels and chorea in graves' disease.

Leblicq C, Duval M, Carmant L, Van Vliet G, Alos N.

Pediatrics. 2013 Feb;131(2):e616-9. doi: 10.1542/peds.2012-0686.

[Choreatic syndrome at 79 years old: late manifestation of Huntington's chorea].

Vachalova I, Golden V, Großkopf J, Heckmann JG.

Nervenarzt. 2013 Dec;84(12):1502-3. doi: 10.1007/s00115-013-3948-8. German. No abstract available.

Huntington's disease: easing the NMDAR traffic jam.

Daggett A, Yang XW.

Nat Med. 2013 Aug;19(8):971-3. doi: 10.1038/nm.3283. No abstract available.

Predictive gene testing for Huntington disease and other neurodegenerative disorders.

Wedderburn S, Panegyres PK, Andrew S, Goldblatt J, Liebeck T, McGrath F, Wiltshire M, Pestell C, Lee J, Beilby J.

Intern Med J. 2013 Dec;43(12):1272-9. doi: 10.1111/imj.12176.

A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Simmons DA, Belichenko NP, Yang T, Condon C, Monbureau M, Shamloo M, Jing D, Massa SM, Longo FM.

J Neurosci. 2013 Nov 27;33(48):18712-27. doi: 10.1523/JNEUROSCI.1310-13.2013. Erratum in: J Neurosci. 2014 Jan 29;34(5):2012.

Family history in juvenile Huntington disease: do the signs point to yes" or "very doubtful"?"

Lehman RK, Nance M.

Neurology. 2013 Mar 12;80(11):976-7. doi: 10.1212/WNL.0b013e31828728ce.

The Q175 mouse model of Huntington's disease shows gene dosage- and age-related decline in circadian rhythms of activity and sleep.

Loh DH, Kudo T, Truong D, Wu Y, Colwell CS.

PLoS One. 2013 Jul 30;8(7):e69993. doi: 10.1371/journal.pone.0069993.

In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system.

Bari M, Battista N, Valenza M, Mastrangelo N, Malaponti M, Catanzaro G, Centonze D, Finazzi-Agrò A, Cattaneo E, Maccarrone M.

FEBS J. 2013 Jul;280(14):3376-88. doi: 10.1111/febs.12329.

MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition.

Taylor DM, Moser R, Régulier E, Breuillaud L, Dixon M, Beesen AA, Elliston L, Silva Santos Mde F, Kim J, Jones L, Goldstein DR, Ferrante RJ, Luthi-Carter R.

J Neurosci. 2013 Feb 6;33(6):2313-25. doi: 10.1523/JNEUROSCI.4965-11.2013.

β-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease.

Vittori A, Orth M, Roos RA, Outeiro TF, Giorgini F, Hollox EJ; REGISTRY investigators of the European Huntington’s Disease Network..

J Huntingtons Dis. 2013 Mar 27;2(1):107-124.

Experience with intramuscular zuclopenthixol and medroxyprogesterone acetate in the treatment of agitation and aggression in Huntington's disease.

Rej S, Desautels R.

J Neuropsychiatry Clin Neurosci. 2013 Summer;25(3):E33-4. doi: 10.1176/appi.neuropsych.12070164. No abstract available.

CNR1 variation is associated with the age at onset in Huntington disease.

Kloster E, Saft C, Epplen JT, Arning L.

Eur J Med Genet. 2013 Aug;56(8):416-9. doi: 10.1016/j.ejmg.2013.05.007.

Chorea.

Pandey S.

J Assoc Physicians India. 2013 Jul;61(7):471-4, 483. Review.

Rhes deletion is neuroprotective in the 3-nitropropionic acid model of Huntington's disease.

Mealer RG, Subramaniam S, Snyder SH.

J Neurosci. 2013 Feb 27;33(9):4206-10. doi: 10.1523/JNEUROSCI.3730-12.2013.